Sleep studies in pwCF of all ages showed a direct correlation between the presence of nocturnal hypoxemia and lung disease severity. Nocturnal hypoxemia is also a common finding in pwCF. The reported prevalence of OSA in pwCF varies widely, being as high as 70% in children and up to 3.9% in adults. ![]() The prevalence of OSA in the general population is up to 38%, with (overweight) males and elderly people most likely to be affected. An apnea-hypopnea index (AHI) of ≥ 5/h is required for diagnosis of OSA. The gold standard technique for diagnosing SDB is overnight, in-laboratory polysomnography (PSG), as recommended by the American Academy of Sleep Medicine (AASM). Īs with other chronic obstructive lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, pwCF of all ages may also have sleep-disordered breathing (SDB), mainly obstructive sleep apnea (OSA) and nocturnal hypoxemia. Due to advances in the treatment of people with cystic fibrosis (pwCF), life expectancy has increased to more than 50 years of age and the number of adults with CF now exceeds the number of children with the disease. Mortality and morbidity are mainly caused by lung involvement with progressive obstructive lung disease, hyperinflation, impaired gas exchange and end-stage respiratory failure. The organs that are primarily affected are the lungs and the gastro-intestinal tract, leading to progressive lung damage and malnutrition. This results in disturbed anion transport (Cl − and HCO 3 −) through epithelial cell membranes and therefore to the formation of highly viscous secretions in all exocrine organs. Therefore, we suggest regular PSG and ESS scoring in adult pwCF, regardless of disease severity.Ĭystic fibrosis (CF), an autosomal recessive monogenetic disorder, is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene on chromosome 7. OSA, nocturnal hypoxemia and EDS were common in adult pwCF, but no strong predictors were identified. OSA was best predicted by awake pO 2 (area under the curve 0.66, p = 0.048), while nocturnal hypoxemia was best predicted by ppFEV 1 (AUC 0.74, p = 0.009), awake pO 2 (AUC 0.76, p = 0.006) and awake SpO 2 (AUC 0.71 p = 0.025). Eight pwCF (15%) had an ESS score > 10 (indicating EDS). Nocturnal hypoxemia was found in 25% of participants and this was associated with ppFEV 1 ( p = 0.014), awake oxygen saturation (SpO 2 p = 0.021) and awake partial pressure of oxygen (pO 2 p = 0.003) there were no significant differences in age, lung function and BMI were found for pwCF with versus without OSA (all p > 0.05). ![]() Overall AHI was in the normal range (4.5 ± 4.0/h) 21/52 pwCF (40%) had an apnea-hypopnea index > 5/h. ![]() ResultsĪ total of 52 adult pwCF were included (mean age 30.7 ± 8.0 years, mean percent predicted forced expiratory volume in 1 s of 52.1 ± 14.8). Demographic and clinical data (body mass index, pulmonary function, capillary blood gases) were collected. EDS was determined using the Epworth Sleepiness Scale (ESS). Methodsįull overnight polysomnography (PSG) was performed. The aim of this study was to collect data on sleep parameters, EDS and pulmonary function from a large cohort of adult pwCF. Most of the data showing this originates from children and adolescents. Obstructive sleep apnea (OSA), nocturnal hypoxemia and excessive daytime sleepiness (EDS) are common comorbidities in people with cystic fibrosis (pwCF).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |